Twitter | Pretraživanje | |
Genentech
Official Twitter Site for Genentech. See our community guidelines here:
6.739
Tweetovi
244
Pratim
108.034
Osobe koje vas prate
Tweetovi
Genentech 20 h
studying the humble fruit fly could help advance regenerative medicine? Grab some earbuds to learn more in the final episode of Season 3, where Heinrich Jasper explains how his research could aid in extending health.
Reply Retweet Označi sa "sviđa mi se"
Genentech 4. velj
Thanks for everything you do to support the community! We’re excited to join you in NYC later this month.
Reply Retweet Označi sa "sviđa mi se"
Genentech 31. sij
We were named one of the for Commuters! One of our 2020 sustainability goals is to reduce CO2 emissions from transportation activities by 10%. Learn more about our efforts to create an environmentally sustainable future:
Reply Retweet Označi sa "sviđa mi se"
Genentech 28. sij
This National , learn how more than 1,300 of our employees volunteer their time as mentors to inspire the next generation of scientists, innovators and critical thinkers.
Reply Retweet Označi sa "sviđa mi se"
Genentech 28. sij
Check out our new study in from Jason Hackney and colleagues which identifies causal genes for age-related macular degeneration, a leading cause of vision loss.
Reply Retweet Označi sa "sviđa mi se"
Genentech 28. sij
ICYMI: The is reviewing our combination for the most common type of under its Real-Time Oncology Review pilot program. Learn more:
Reply Retweet Označi sa "sviđa mi se"
Genentech 27. sij
We're proud to help support this important research initiative around in clinical trials with our partner !
Reply Retweet Označi sa "sviđa mi se"
Genentech 27. sij
Is it possible to extend human health? Check out the final episode of Season 3 to learn how we might be able to engage our body's own repair mechanisms to delay the onset of age-related disease.
Reply Retweet Označi sa "sviđa mi se"
Genentech 27. sij
: Our combination for the most common type of is being reviewed under the Real-Time Oncology Review pilot program, which aims to get treatments to patients faster.
Reply Retweet Označi sa "sviđa mi se"
Genentech 24. sij
Today we shared an update on our Phase III study evaluating our immunotherapy for a specific type of bladder cancer. Learn more:
Reply Retweet Označi sa "sviđa mi se"
Genentech 23. sij
: Pivotal trial evaluating our spinal muscular atrophy () medicine meets primary endpoint in infants with Type 1
Reply Retweet Označi sa "sviđa mi se"
Genentech proslijedio/la je tweet
Adaptive Biotech 22. sij
“We are going after multiple TCRs against multiple targets simultaneously...that’s why we’re excited about this strategy” - CSO Harlan Robins, with VP, Cancer Immunology, Ira Mellman at Learn more about our partnership:
Reply Retweet Označi sa "sviđa mi se"
Genentech proslijedio/la je tweet
JExpMed 21. sij
Cancer mutations create neoantigens that are of great interest for immunotherapy, but their accurate identification remains a challenge. researchers show that mutation position is an important determinant for immunogenicity
Reply Retweet Označi sa "sviđa mi se"
Genentech proslijedio/la je tweet
Adaptive Biotech 21. sij
Join co-founder & Chief Scientific Officer, Harlan Robins, and Vice President, Cancer Immunology, Ira Mellman at for a fireside chat on progress, challenges, and what’s next for cancer immunotherapy. Read more about our partnership:
Reply Retweet Označi sa "sviđa mi se"
Genentech 21. sij
Tomorrow at , Ira Mellman, Vice President, Cancer Immunology, joins Co-founder & Chief Scientific Officer, Harlan Robins, for a fireside chat on cancer immunotherapy. Read more about our partnership with Adaptive.
Reply Retweet Označi sa "sviđa mi se"
Genentech 21. sij
We’re honored to be named one of Best Employers for Diversity! Learn how we’re fostering a culture where difference is valued and celebrated:
Reply Retweet Označi sa "sviđa mi se"
Genentech 17. sij
Neoantigens result from cancer-specific genetic mutations. In , a team led by Aude-Hélène Capietto, Suchit Jhunjhunwala & Lélia Delamarre identify traits of these mutations that could help prioritize targets for future cancer .
Reply Retweet Označi sa "sviđa mi se"
Genentech 17. sij
Looking for in-flight entertainment on your way home from ? Tune in to our latest episode to hear from Mark Lee and David Shames about how could help deliver personalized care to those who need it.
Reply Retweet Označi sa "sviđa mi se"
Genentech 16. sij
DYK that of the nearly 4,000 “druggable” targets known today, only about a quarter have been drugged or have a medicine that can impact them? See how we’re working to address this long-standing challenge with our partners.
Reply Retweet Označi sa "sviđa mi se"
Genentech 15. sij
Solving the challenges facing the healthcare industry is best tackled as a team. That’s why we have 220 ongoing around the world. Learn more about our continued commitment to .
Reply Retweet Označi sa "sviđa mi se"